Drugs / F18-DCFPyL
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06361810 | Oct 2025 → Jan 2031 | clear cell renal carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05009979 | Jan 2023 → Nov 2024 | hepatocellular carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase not stated1 trial | ||||||
| — | NCT04809584 | — | prostate cancer | Stanford University | Approved for marketing | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F18-DCFPyL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04809584 ↗ |
| Known as | 18FDCFPyL | “The radioactive study agent, 18FDCFPyL, combined with PET/MRI scan may be able to identify smaller tumors than the standard of care contrast-enhanced CT or MRI scan.” NCT04809584 ↗ |
| Modality | Diagnostic / imaging agent | “18F-DCFPyL, a second generation PSMA PET agent” NCT05009979 ↗ |
| Route | Intravenous | “Participant will be injected iv” NCT04809584 ↗ |